About Echo Therapeutics (OTCMKTS:ECTE)
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Echo Therapeutics (OTCMKTS:ECTE) Frequently Asked Questions
What is Echo Therapeutics' stock symbol?
Echo Therapeutics trades on the OTCMKTS under the ticker symbol "ECTE."
How were Echo Therapeutics' earnings last quarter?
Echo Therapeutics Inc (OTCMKTS:ECTE) posted its quarterly earnings data on Friday, August, 12th. The medical device company reported ($0.82) EPS for the quarter. During the same quarter in the prior year, the firm earned ($0.97) EPS. View Echo Therapeutics' Earnings History.
Who are some of Echo Therapeutics' key competitors?
Some companies that are related to Echo Therapeutics include Coldwater Creek (CWTRQ), First NBC Bank (FNBC), Directview (DIRV), Cosi (COSIQ), Baxano Surgical (BAXSQ), Imris (IMRSQ), Savient Pharmaceuticals (SVNTQ), UniTek Global Services (UNTKQ), DS Healthcare Group (DSKX), Corinthian Colleges (COCOQ), International Shipholding (ISHCQ), Kid Brands (KIDB), diaDexus (DDXS), Cache (CACH), China Gerui Advanced Materials Group (CHOPF), Gordmans Stores (GMANQ), Velti (VELTF) and NephroGenex (NRXGQ).
Who are Echo Therapeutics' key executives?
Echo Therapeutics' management team includes the folowing people:
- Alan W. Schoenbart CPA, Chief Executive Officer, Chief Financial Officer, Secretary, Director (Age 58)
How do I buy Echo Therapeutics stock?
Shares of Echo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Echo Therapeutics' stock price today?
One share of Echo Therapeutics stock can currently be purchased for approximately $0.01.
How big of a company is Echo Therapeutics?
Echo Therapeutics has a market capitalization of $100,000.00.
How can I contact Echo Therapeutics?
Echo Therapeutics' mailing address is 99 WOOD AVENUE SOUTH SUITE 302, ISELIN NJ, 08830. The medical device company can be reached via phone at 732-549-0128 or via email at [email protected]
MarketBeat Community Rating for Echo Therapeutics (ECTE)MarketBeat's community ratings are surveys of what our community members think about Echo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Echo Therapeutics (OTCMKTS:ECTE) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Echo Therapeutics (OTCMKTS:ECTE) Earnings History and Estimates Chart
Echo Therapeutics (OTCMKTS ECTE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/14/2014||Q214||($0.23)||($0.31)||$22.56 million||$19.10 million||View||N/A|
|5/9/2014||Q114||($0.26)||($0.23)||$0.02 million||$0.02 million||View||N/A|
|3/27/2014||Q413||($0.36)||($0.35)||$0.02 million||($0.04) million||View||N/A|
|8/8/2013||Q2 2013||($0.81)||($0.51)||$10.00 million||$22.56 million||View||N/A|
|5/10/2013||Q1 2013||($0.10)||($0.13)||$0.01 million||View||N/A|
Echo Therapeutics (OTCMKTS:ECTE) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Echo Therapeutics (OTCMKTS:ECTE)
No dividend announcements for this company have been tracked by MarketBeat.com
Echo Therapeutics (OTCMKTS ECTE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.00%
Echo Therapeutics (OTCMKTS ECTE) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/20/2015||Alan Wayne Schoenbart||CFO||Buy||2,500||$1.44||$3,600.00|| |
|5/20/2015||Scott Wayne Hollander||CEO||Buy||8,000||$1.48||$11,840.00|| |
|6/30/2014||Mark Nordlicht||Major Shareholder||Buy||65,739||$2.20||$144,625.80|| |
|6/26/2014||Mark Nordlicht||Major Shareholder||Buy||17,300||$2.20||$38,060.00|| |
|6/24/2014||Mark Nordlicht||Major Shareholder||Buy||16,961||$2.20||$37,314.20|| |
|12/10/2013||Mark Nordlicht||major shareholder||Buy||69,569||$2.75||$191,314.75|| |
|3/22/2013||Robert F Doman||Director||Buy||15,000||$0.80||$12,000.00|| |
|3/21/2013||William Grieco||Director||Buy||30,000||$0.76||$22,800.00|| |
|8/23/2012||James Francis Smith||Director||Buy||20,000||$1.47||$29,400.00|| |
Echo Therapeutics (OTCMKTS ECTE) News Headlines
Echo Therapeutics (OTCMKTS:ECTE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Echo Therapeutics (OTCMKTS:ECTE) Income Statement, Balance Sheet and Cash Flow Statement
Echo Therapeutics (OTCMKTS ECTE) Stock Chart for Saturday, January, 20, 2018